First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting
2024

First Results from the FINE-REAL Study on Finerenone Use in CKD and T2D

Sample size: 504 publication Evidence: moderate

Author Information

Author(s): Susanne B. Nicholas, Ricardo Correa-Rotter, Nihar R. Desai, Lixin Guo, Sankar D. Navaneethan, Kevin M. Pantalone, Christoph Wanner, Stefanie Hamacher, Samuel T. Fatoba, Andrea Horvat-Broecker, Antonio Garreta-Rufas, Alain Gay, Martin Merz, David C. Wheeler

Primary Institution: Department of Medicine, Division of Nephrology, David Geffen School of Medicine at University of California, Los Angeles

Hypothesis

The FINE-REAL study aims to evaluate the characteristics and treatment patterns of participants treated with finerenone in clinical practice.

Conclusion

Finerenone was initiated in patients with CKD and T2D across various clinical practices, with low rates of treatment discontinuation and hyperkalemia.

Supporting Evidence

  • Of 556 participants enrolled, 504 were included in the analysis.
  • 92.3% of participants had uninterrupted treatment after 7 months.
  • Hyperkalemia occurred in 5.0% of participants, with no serious outcomes.

Takeaway

Doctors are using a new medicine called finerenone to help people with kidney problems and diabetes, and most people are doing well with it.

Methodology

This is a prospective, single-arm, non-interventional study of patients initiated on finerenone as part of their routine care.

Limitations

The study has a short follow-up time and is observational, meaning causality cannot be established.

Participant Demographics

Participants had a mean age of 66.1 years, with 60.7% male and a median duration of type 2 diabetes of 14 years.

Digital Object Identifier (DOI)

10.1007/s40620-024-02070-y

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication